Small Molecule Targeted Cancer Therapy Market Growth Supported by Key Drivers, Expected to Hit $120.34 Billion by 2029

 Grab 20% Off With Code ONLINE20 On Global market Reports — Evaluate Global Trends, Market Risks, and Competitive Intelligence

 

 How Has the Small Molecule Targeted Cancer Therapy Market Evolved in Terms of Size and Value From 2025 to 2029?
 The small molecule targeted cancer therapy market size has grown strongly in recent years. It will grow from $78.07 billion in 2024 to $85.35 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to increasing better understanding of cancer biology, rising approval of inhibitors, rising cancer prevalence, rising early adoption of personalized medicine, and expansion of oncology clinical trials.
 
 The small molecule targeted cancer therapy market size is expected to see strong growth in the next few years. It will grow to $120.35 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to increasing demand for precision oncology, rising investment in next-generation inhibitors, rising healthcare expenditure in emerging markets, increasing demand for the therapies, and growing strategic collaborations. Major trends in the forecast period include a focus on tumor-agnostic therapies, the development of allosteric modulators, the adoption of artificial intelligence in drug discovery, the adoption of oral targeted therapies, and a shift towards combination treatment strategies.
 
 Get your free report sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=28331&type=smp
 
 What Are the Essential Drivers Propelling the Small Molecule Targeted Cancer Therapy Market Forward?
 The growing demand for personalized medicine is expected to propel the growth of the small molecule targeted therapy market going forward. Personalized medicine refers to a medical approach that tailors the prevention, diagnosis, and treatment of diseases to the individual characteristics of each patient. The demand for personalized medicine is rising due to the growing need for targeted treatments that improve efficacy and reduce adverse effects. Small molecule targeted therapy helps address the demand for personalized medicine by enhancing treatment specificity, improving patient response, minimizing side effects, and enabling therapies tailored to individual genetic and molecular profiles. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the US Food and Drug Administration (FDA) granted approval for 16 new personalized treatments for rare disease patients, marking a substantial increase from the six approvals in 2022. Therefore, the growing demand for personalized medicine is driving the growth of the small molecule targeted therapy market.
 
 How Is the Small Molecule Targeted Cancer Therapy Market Structured Across Its Key Segment Categories?
 The small molecule targeted cancer therapy market covered in this report is segmented as
 
 1) By Therapy Type: Tyrosine Kinase Inhibitors, Proteasome Inhibitors, Histone Deacetylase Inhibitors, PARP Inhibitors, CDK Inhibitors, BCL-2 Inhibitors, mTOR Inhibitors, Other Small Molecule Inhibitors
 2) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Prostate Cancer, Other Cancer Types
 3) By Mode Of Administration: Oral, Intravenous, Other Modes
 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Direct Sales
 5) By End User: Hospitals, Specialty Clinics, Research Institutes, Other End Users
 
 Subsegment:
 1) By Tyrosine Kinase Inhibitors: EGFR Inhibitors, VEGFR Inhibitors, ALK Inhibitors, BCR-ABL Inhibitors, HER2 Inhibitors
 2) By Proteasome Inhibitors: Bortezomib, Carfilzomib, Ixazomib
 3) By Histone Deacetylase Inhibitors: Pan-Histone Deacetylase Inhibitors, Class-specific Histone Deacetylase Inhibitors
 4) By PARP Inhibitors: Olaparib, Niraparib, Rucaparib, Talazoparib
 5) By CDK Inhibitors: CDK4/6 Inhibitors, CDK1/2 Inhibitors, Pan-CDK Inhibitors
 6) By BCL-2 Inhibitors: Venetoclax, Navitoclax
 7) By mTOR Inhibitors: Rapamycin Analogs (Rapalogs), ATP-competitive mTOR Inhibitors, Dual mTOR/PI3K Inhibitors
 8) By Other Small Molecule Inhibitors: MEK Inhibitors, PI3K Inhibitors, RAF Inhibitors
 
 Which Emerging Trends Are Shaping the Future of the Small Molecule Targeted Cancer Therapy Market?
 Major companies operating in the small molecule targeted cancer therapy market are focusing on innovative therapy, such as structure-based drug design, to develop highly selective inhibitors that target specific oncogenic mutations, minimize off-target effects, and improve patient outcomes. Structure-based drug design is a method that uses the 3D structure of a target protein to design small molecules that bind precisely to it, improving drug effectiveness and reducing side effects. For instance, in December 2022, Mirati Therapeutics, a US-based oncology company, announced KRAZATI (adagrasib) as a targeted therapy for adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic therapy approved by the U.S. Food and Drug Administration (FDA), a US-based government agency. This approval provides a new treatment option for patients with difficult-to-treat KRAS G12C-mutated non-small cell lung cancer, addressing an important unmet medical need. KRAZATI works by selectively inhibiting the KRAS G12C mutant protein, which is involved in cancer cell proliferation and survival.
 
 Which Major Organizations Influence the Direction of the Small Molecule Targeted Cancer Therapy Market?
 Major companies operating in the small molecule targeted cancer therapy market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Novartis International AG, AstraZeneca plc, Bristol-Myers Squibb Company, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., and Ipsen Biopharmaceuticals Inc.
 
 Get the detailed small molecule targeted cancer therapy market report today
 https://www.thebusinessresearchcompany.com/report/small-molecule-targeted-cancer-therapy-global-market-report
 
 Which Region Holds the Largest Share of the Small Molecule Targeted Cancer Therapy Market?
 North America was the largest region in the small molecule targeted cancer therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in small molecule targeted cancer therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
 
 Contact Us:
 
 The Business Research Company: https://thebusinessresearchcompany.com/ 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 Email: info@tbrc.info 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company